On this page
At a glance / CoreAge Rx
Our take
A catalog that discusses energy and metabolic care is not automatically a MOTS-c catalog. CoreAge’s checked public lineup describes other products, while a current MOTS-c offer was not established. Use this review to examine that product gap and the service agreement without turning related marketing language, a commission relationship or a starting rate into evidence of equivalence.
- Review scope
- Provider brand; target-product availability not verified
- Commercial relationship
- Approved affiliate partner; product placement not activated
- State and pharmacy match
- Confirm for the exact proposed prescription
- Refund terms to resolve
- FAQ promises a full denial refund; the detailed policy allows a $50–$100 consultation deduction.
- Renewal terms to resolve
- FAQ says no automatic rebilling; detailed terms permit subscription renewals.
Useful details
- Public service and policy information can be examined before an assessment.
- The brand and the proposed product can be evaluated separately.
What to weigh
- The checked catalog does not establish the target peptide offering.
- Refund and renewal wording requires plan-specific confirmation.
- The dispensing pharmacy and patient-state eligibility need verification.
A review of published information, not a treatment experience or a clinical quality rating. Source check: 2026-10-28.
The first question
A provider’s interest in longevity does not establish a MOTS-c offering. CoreAge is an affiliate partner, but our current catalog check did not establish the exact product relevant to this publication. Research about mitochondrial biology and a commercial care pathway are separate subjects. This review keeps the catalog finding visible so that a reader does not mistake a brand mention for a product recommendation.
How to use this review
Before considering a future listing, ask what preparation is proposed, what evidence supports the intended use, and how the care process addresses uncertainty. A study of naturally occurring MOTS-c during exercise cannot by itself justify an administered commercial product. The provider should be able to explain the distance between those facts. Pair that discussion with a concrete written account of the assessment, pharmacy and follow-up rather than treating a biological mechanism as the entire service description. Our provider terms comparison shows which catalog entries currently identify a MOTS-c product.
The catalog does not answer the research question
CoreAge publishes other wellness products, but the checked catalog did not establish a MOTS-c offering. Neither an NAD+ listing nor a discussion of metabolic biology closes that gap. Keep three questions separate: what researchers investigated, what CoreAge currently lists and what a clinician might consider. This review verifies none of those by association with the others.
Ask what a program would actually include
If CoreAge supplies a MOTS-c proposal, request the ingredient, route and included services. Ask which follow-up or testing is required, which is optional and how its purpose would be explained clinically. A more elaborate service package does not itself establish a metabolic benefit. The clinician's rationale and the written service description should remain independently understandable.
Put the cost on a defined calendar
No verified MOTS-c quote was available from the checked catalog. A rate attached to another product should not become an estimate here. Request charge dates and the full commitment for the proposed service. Also reconcile the FAQ's renewal and refund language with the detailed policy; ask what you would retain or lose financially if prescribing is declined. The current MOTS-c access briefing keeps policy scope distinct from a provider’s catalog.
What would make this worth revisiting
A current product-specific listing, a state-specific care answer and clear payment terms would make a fresh comparison possible. Ask for those documents before interpreting CoreAge's general wellness presentation as a MOTS-c option. Any eventual care decision would still need a separate discussion of the evidence for the proposed use; catalog clarity cannot supply that clinical conclusion.
Common questions
Does the NAD+ listing establish MOTS-c availability?
No. NAD+ is named in the current lineup; a MOTS-c product was not established by this catalog check. One product listing is not evidence of another.
Can this review give an ongoing MOTS-c total?
No verified current MOTS-c offering or quote was found in the checked lineup. A price for another ingredient would not fill that missing field.
What makes the renewal question unresolved?
The FAQ says no automatic rebilling, while detailed terms describe subscription renewals. Confirm the particular service agreement instead of assuming either statement applies to every plan.
Sources & further reading
Primary research, provider documents and policy sources used in this article. Sources do not endorse this publication.
- CoreAge Rx current catalog
- CoreAge Rx product help
- CoreAge Rx FAQ
- CoreAge Rx returns and refund policy
Source review: 2026-10-28. Provider terms and policy documents can change.